Cooley M&A

JANUARY 22, 2025

Portfolio optimization through divestitures of noncore assets In addition to pharmas smaller appetite in 2024, pharma companies continued to slim down by shedding nonessential assets to sharpen their strategic focus on core products. Similarly, Novo Holdings $16.5

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64

The Deal

OCTOBER 17, 2023

But some subsectors, such as beauty, fragrance, residential services and medical spas, remained active as risk-off investors shifted deal activity toward categories they view as less discretionary, according to Leonhardt. Public markets, however, have been tepid, with the much-awaited IPO of L Catterton Management Ltd.

M&A 64

M&A IPO Retail Medical 64

Mergers and Inquisitions

NOVEMBER 1, 2023

The short answer to #1 is that healthcare private equity firms operate in specific verticals with stable-ish cash flows, such as healthcare services, nursing facilities, medical devices, equipment, and healthcare IT. They do not invest in risky biotech startups attempting to cure cancer (at least not within their traditional PE portfolios).

Private Equity 59

Private Equity Healthcare Equities Middle Market 59

Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 23, 2024

Strained access to public markets and funding The IPO market remained relatively inactive in 2023, leading many life sciences companies looking to raise funds to turn to other exit strategies. Additional major acquisitions of 2023 included Pfizer’s acquisition of Seagen for $43 billion and Merck’s acquisition of Prometheus for $10.8

M&A 52

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 52

Growth Business

SEPTEMBER 13, 2023

Investment range: £50,000 – £3m Sectors: fintech, insurtech, regtech, digital health and medical technology, artificial intelligence and machine learning, consumer services, digital media, semiconductors and displays, cybersecurity, enterprise software, autonomous systems and human computer interfaces, novel materials and quantum technology.

Capital 52

Capital Business Funds Investment 52

Cooley M&A

JANUARY 25, 2023

Similarly, we expect sponsors to actively pursue carve out opportunities – like Francisco Partners’ carve out acquisition of the data and analytics assets from IBM’s Watson Health business – in 2023 as tech giants streamline their portfolios to focus on their core businesses.

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52